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Colorectal cancer (CRC) is a major cause of death in Western countries. A combination of 
nature (genetic susceptibility, gender) and nurture (environmental factors, life style) 
determines an individual’s risk of developing CRC. Cancer development is the result of a 
complex sequence of cellular events via molecular pathways. Most CRCs are preceded by 
adenomatous polyps. These adenomas are histologically benign, but a percentage of these 
will inevitably undergo malignant transformation, known as the adenoma-carcinoma 
sequence. 
Patients with certain germline genetic defects develop multiple colorectal polyps and have 
consequently an extremely high risk of developing cancer. Although these patients constitute 
only a small proportion of all CRC cases, this group with hereditary polyposis syndromes 
offers opportunities for research. From the scientific point of view, these patients provide 
insight into cancer development as they will almost certainly develop CRC. From the patient’s 
and doctor’s point of view, it is important to develop guidelines for diagnosis, treatment, and 
surveillance. Moreover, identification of family members at risk will allow timely screening and 
treatment, and consequently prevention from cancer development.  
This thesis describes several clinical aspects of various hereditary polyposis syndromes, 
including familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), and 
PTEN hamartoma tumor syndrome (PHTS), and provides recommendations for clinical 
management of these syndromes. 
 
Part I Familial adenomatous polyposis (FAP) 
The main clinical characteristic of FAP is the development of a multitude of colorectal polyps, 




Genetically, FAP is an autosomal dominant condition caused by a germline mutation in the 
tumor suppressor gene adenomatous polyposis coli (APC), which is located on chromosome 
 10 
5q21-22 (2). The main tumor suppressing function of APC resides in its capacity to regulate 
the Wnt signal transduction pathway. In the absence of Wnt signals, a dedicated complex of 
proteins, including APC, axin, and glycogen synthase kinase-3β (GSK3β) phophorylates β-
catenin, resulting in its ubiquitylation and degradation by the proteasome. Signalling by Wnt 
factors prevents forming of a  protein/APC complex. As a result, β-catenin is stabilized and 
translocates into the nucleus, where it interacts with nuclear T-cell-factor (TCF) transcription 
factors to drive the transcription of specific target genes like MYC and cyclin D1. These play a 
role in cell proliferation, apoptosis, and cell-cycle progression and thus are relevant in tumor 
formation (3). Since the identification of the APC gene in 1991 (2,4,5) as the cause of FAP,  
several reports described an obvious association between the location of a certain APC 
mutation and the number of colorectal polyps in the individual patient. In Chapter 2 of this 
thesis, these genotype-phenotype correlations in FAP are reviewed.  
 
Surgical considerations 
Clinically, patients with a germline APC gene mutation develop hundreds to thousands 
colorectal adenomatous polyps from adolescence. Without treatment, virtually all patients will 
develop CRC before the age of 40 years (6). To prevent development of CRC, patients need 
frequent colonoscopic examinations (7). In the case of endoscopically unmanageable 
polyposis, patients are referred for a prophylactic colectomy. The two main surgical options are 
subtotal colectomy with ileorectal anastomosis (IRA) and total proctocolectomy with ileal 
pouch-anal anastomosis (IPAA). After IRA, the rectum is left situ, whereas after IPAA the 
rectum is totally removed. The IRA procedure has a lower risk of complications and a more 
favourable functional outcome than IPAA surgery (8,9). However, a disadvantage of IRA is the 
remaining risk of developing polyps and cancer in the rectum. After IPAA, there is virtually no 
risk of developing rectal cancer because the rectal mucosa is removed. For most patients with 
more than 10-15 rectal adenomas, an IPAA is recommended (7). In patients with few or no 
rectal polyps the surgical decision needs a careful deliberation of the pros and cons of both 
procedures. It might be helpful to additionally consider genetic information in the decision. In 
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Chapter 3 and 4, we assessed whether the risk of rectal excision and rectal cancer after IRA 
for patients with different severity of polyposis can be predicted by the APC mutation site.  
 
Fertility 
As prophylactic surgery is usually performed in the second or third decade of life, also future 
factors have to be taken into account, including family planning. Fertility problems are a 
common long-term complication after extended abdominal surgery, mainly thought to be 
caused by adhesions which are provoked by surgical damage (9). A previous study showed 
significantly more fertility problems in female FAP patients who had an IPAA procedure, 
compared to those who had undergone an IRA (11). Chapter 5 contains the results of a study 
among Dutch female FAP patients addressing fertility problems due to colorectal surgery.  
 
Extracolonic manifestations 
Beside colorectal polyposis, FAP patients can suffer from a variety of other disease 
characteristics (12). These extra-colonic manifestations include duodenal adenomas and 
duodenal cancer; several malignancies including thyroid cancer, hepatoblastoma, and brain 
tumors; benign tumors including gastric polyps, adrenal adenomas, osteomas, epidermoid 
cysts, fibromas, lipomas, and desmoid tumors; other abnormalities as congenital hypertrophy 
of the retinal pigment epithelium (CHRPE) and supernumerary teeth (12). By prophylactic 
colectomy, the colorectal cancer risk of FAP patients decreases and life expectancy 
increases. As a consequence, extracolonic manifestations have become relatively more 
important. The clinically most threatening are duodenal cancer and desmoid tumours, since 
these cause significant morbidity and mortality in FAP patients (13,14,15).  
 
Duodenal adenomas and duodenal cancer 
Almost all FAP patients develop duodenal adenomas: The cumulative incidence was 
calculated to be 90% at age 70 (16). FAP patients have a nearly 5% risk of duodenal cancer 
(16). As duodenal cancer is difficult to treat, it is important to prevent development of duodenal 
cancer and to detect and remove precancerous lesions. In 1989 a classifcation was proposed 
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to determine the severity of duodenal polyposis based on polyp number, size, histology, and 
severity of dysplasia (17). This Spigelman classification is currently used to estimate the 
probability of duodenal cancer and to determine surveillance intervals (7). In the case of 
advanced duodenal adenomatosis and a high cancer risk, performing a prophylactic 
duodenectomy should be considered. However, this procedure has a substantial risk of 
complications. To gain more insight into the clinical course of FAP patients with advanced 
duodenal polyposis and/or duodenal cancer, a retrospective study was performed addressing 
this topic (Chapter 6).  
 
Type II diabetes and FAP 
Recent genome wide analysis studies (GWAS) showed certain polymorphisms to be 
associated with type II diabetes (18). Remarkably, these polymorphisms are known to be 
involved in the Wnt pathway. Chapter 7 describes a concise research project which aimed to 
assess whether type II diabetes is more common in FAP patients than in the general 
population. 
 
Part II Desmoid tumors 
Desmoid tumors belong to the broad group of histologically benign fibrous tumors known as 
fibromatoses, and more specifically to the deep (musculo-aponeurotic) fibromatoses (19). 
Although benign in name, these tumors have an unpredictable and sometimes aggressive 
growth pattern, leading to serious morbidity or even mortality by local infiltration and pressure 
on surrounding vital structures. In Chapter 8 characteristics of patients with desmoid tumors in 
the Dutch FAP population are described.  
 
Sporadic versus FAP-related desmoid tumors 
Desmoid tumors are extremely rare in the general population, but do occur in about 10% of 
FAP kindreds (20). As FAP is a rare syndrome, most desmoids diagnosed by pathologists and 
other physicians are sporadic ones. However, because of the severity of FAP for both a patient 
and his/her family members, it is crucial to detect patients with FAP. In Chapter 9 clinical 
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characteristics of sporadic and FAP-related desmoid tumors were compared, to assess 
whether an underlying FAP syndrome can be identified by clinical variables.  
 
Risk factors 
The etiology of desmoids tumors is yet unelucidated. Several previous studies suggested risk 
factors for desmoid development, including female hormones, pregnancy, abdominal surgery, 
a positive family history of desmoids, and distal APC gene mutations (20). In Chapter 10 risk 
factors for desmoid development were assessed in a large international cohort of FAP patients. 
 
Management 
The treatment of desmoid tumors is a topic of controversy (21). Due to the complex 
mesenterial location of most FAP-related desmoid tumors, and because surgical trauma can 
provoke desmoid growth, surgery is not an attractive option. Generally, the initial 
pharmacological treatment consists of non-steroidal anti-inflammatory drugs (NSAIDs) and/or 
hormonal therapy, most often tamoxifen. More aggressive therapeutic options include cytotoxic 
chemotherapy and radiation therapy. However, despite intensive therapy desmoid tumors can 
still cause severe morbidity and mortality, especially if located at intra-abdominal sites. 
Because desmoid tumors are rare, initiating a randomized controlled trial is difficult. Moreover, 
the unpredictable growth pattern of desmoid tumors makes interpretation of the effects of 
therapies difficult. To gain insight into therapeutic strategies, in Chapter 11 the management of 
desmoid tumors in Dutch FAP patients was evaluated.  
 
Part III Other polyposis syndromes 
Beside FAP, there is a spectrum of other hereditary syndromes with polyposis as a clinical 
feature. Because these syndromes are rare, establishing evidence-based guidelines for 





MUTYH-associated polyposis  
The most recently discovered polyposis syndrome is MUTYH-associated polyposis (MAP). In 
2002, mutations in the base-excision repair gene MUTYH were identified as a cause for 
polyposis (22). Contrary to FAP, MAP has a recessive mode of inheritance and patients with bi-
allelic mutations in the MUTYH gene are affected. Clinically, most MAP patients who present 
symptomatically were on average 45 years at diagnosis and most of them had between ten 
and a few hundred colorectal adenomas (23). Nearly 60% had colorectal cancer at a mean 
age of 48 years (23). Clinically, the MAP phenotype resembles that of an attenuated form of 
APC-associated polyposis (AFAP), and patients with MAP are recommended to undergo the 
AFAP screening protocol (24). However, information on the natural history of MAP is still 
scarce. In Chapter 12, the results of diagnosis and treatment of MAP patients for almost a 
decade were evaluated, with the aim to elucidate the natural history of tumor development in 
MAP. 
 
PTEN hamartoma tumor syndrome 
Germline mutations in the tumor suppressor gene Phosphatase and tensin homolog (PTEN) 
cause a variety of rare syndromes with hamartomatous polyps in several organs as a common 
characteristic. Moreover, patients with PTEN hamartoma tumor syndrome (PHTS) have an 
increased risk of several malignant tumors, particularly of the breast, thyroid, and endometrium 
(25). The mode of inheritance of PHTS is dominant. Within families, the phenotypic expression 
is variable. Guidelines for management include regular surveillance for breast cancer, thyroid 
cancer, and endometrial cancers, which are clearly associated with PHTS (NCCN guidelines 
for detection, prevention, and risk reduction; Genetic/familial high-risk assessment: Breast and 
ovarian – Cowden syndrome. www.nccn.org [accessed 21-12-2010]).  
However, there are also other clinical features with unclear cancer risks, for which no 
guidelines were established. Recent reports showed that the majority of patients with a PTEN 
mutation have colorectal polyposis, and that also colorectal carcinoma is common in these 
patients (26,27,28). In Chapter 13, the frequency and nature of colorectal polyps were 
assessed, and the risk of developing CRC was calculated. 
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Research questions 
The central research question of this thesis is:  
 
How can the diagnosis, surveillance, and management of patients with hereditary polyposis 
syndromes be optimized?  
 
This question is addressed from several perspectives, leading to the subquestions: 
Can genetic information be applied for management decisions in FAP? 
Can risk factors be identified for postoperative fertility problems? 
What is the outcome of patients with advanced duodenal adenomatosis or duodenal cancer? 
What are the implications of recent findings on the Wnt pathway and type II diabetes? 
What are the characteristics of FAP patients with desmoid tumors? 
Can differences between FAP-related and sporadic desmoids be used to predict a FAP 
syndrome? 
What are risk factors for desmoid tumor development? 
What is the outcome of different treatment strategies for desmoid tumors? 
What is the natural course of MUTYH-associated polyposis? 
What is the risk of gastrointestinal lesions in patients with a PTEN mutation? 
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Background and aim: Patients with germline phosphatase and tensin homologue (PTEN) 
mutations develop hamartomatous lesions in several organs and are at increased risk of 
various malignancies. We assessed the lifetime risk of benign and malignant gastrointestinal 
lesions in patients with a proven PTEN mutation. 
Method: Data on sex, mutation, dates of birth, last contact, and diagnosis, location, and type 
of gastrointestinal lesions were collected from nine countries. The lifetime risk of 
gastrointestinal lesions was calculated by Kaplan-Meier methods. 
Results: A total of 156 patients (67 males, 43%) from 101 families with a PTEN mutation 
were included. Patients were born between 1928 and 2008. Benign gastrointestinal polyps 
were reported in 49 patients (31%) at a mean age of 38 years (range 18-62 years) and were 
most often hamartomas. Twenty-two patients (44%) had upper as well as lower 
gastrointestinal lesions, 14 (29%) had only colonic lesions, and 13 (27%) had gastrointestinal 
lesions at unknown sites. The cumulative risk of developing benign gastrointestinal polyps 
was 70% at age 60. Four patients (two males) developed colorectal carcinoma (CRC) at 53, 
57, 59, and 62 years, respectively. The cumulative risk of developing CRC was 18% at age 60. 
Except one carcinoid in the small intestine, no upper gastrointestinal cancers were observed. 
Conclusion: Benign gastrointestinal lesions are common in PTEN mutation carriers. We 
show a three- to fourfold increased lifetime risk of CRC, compared to the general population. 
Colorectal screening of patients with germline PTEN mutations is recommended, starting at 
age 40 years. 
 
What is new in this paper? 
Patients with a germline PTEN mutation have a significant risk of developing benign 
colorectal tumors (70% cumulative risk at age 60) and colorectal cancer (18% cumulative risk 
at age 60). Surveillance of the colorectum is recommended from age the age of 40 years. 
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INTRODUCTION 
PTEN hamartoma tumor syndrome (PHTS) is the collective term for clinical 
syndromes caused by germline mutations in the tumor suppressor Phosphatase and tensin 
homologue, deleted on chromosome ten (PTEN).  
The PTEN gene is located at chromosome 10q23.31. PTEN acts as a tumor suppressor 
by counteracting the important cancer promoting PI3K/Akt signaling pathway. PTEN is also 
involved in regulation of genomic instability, DNA repair, stem cell self-renewal, cellular 
senescence, and cell migration/metastasis.[1]   
Clinical syndromes caused by PTEN mutations include Cowden syndrome, Lhermitte-
Duclos disease, Bannayan-Riley-Ruvalcaba syndrome, and Proteus-like syndrome. A 
common characteristic of these syndromes is the development of hamartomatous tumors 
which can arise from all embryonal layers and therefore occur at various sites of the body. 
Although histologically benign, some lesions have serious consequences, for example 
Lhermitte-Duclos disease (dysplastic cerebellar gangliocytoma), a hamartomatous overgrowth 
of cerebellar tissue which can cause mass effects in the posterior fossa. Beside the benign 
tumors, PHTS patients have an increased risk of developing cancer, particularly cancer of the 
breast and thyroid.[2] Surveillance protocols have been established to allow timely detection 
of (pre)malignant lesions.[3] 
Although colorectal hamartomas and other types of polyps in the gastrointestinal tract 
are common, there are no consistent guidelines for gastrointestinal surveillance in PHTS 
patients. It is notable that information on cancer risks in the PTEN hamartoma tumor 
syndrome are generally derived from studies of individuals who fulfill published clinical 
criteria for Cowden Syndrome but who do not necessarily have an identifiable PTEN 
mutation. In this type of study, several have reported increased risks of colorectal polyps and 
cancer in such patients.[2-5]  
In the present study we assessed the lifetime risk of benign and malignant lesions in 
the gastrointestinal tract in a large international cohort of PTEN mutation carriers and discuss 
the need for colorectal surveillance in these patients. 
  
 
PATIENTS AND METHODS 
Clinical and genetic data on patients with a germline PTEN mutation were obtained from 
clinical genetic centers from nine countries (USA, France, Norway, United Kingdom, 
Germany, Switzerland, Australia, Denmark, The Netherlands). Patients had given informed 
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consent for using clinical data for research purposes and data were gathered anonymously. 
The data collected included information on date of birth, date of last contact, type of PTEN 
mutation, and details on gastrointestinal lesions, including year of diagnosis and type of the 
lesions. The PTEN mutations reported in the study cohort were considered to be deleterious 
based upon the type of the mutation (nonsense, frameshift, or splice site mutation), or upon 
existing literature on this mutation. For mutations that have not been described evidence for 
pathogenicity was obtained by mutation prediction software and/or co-segregation of 
characteristic phenotype within families. Patients with a PTEN and BMPR1A contiguous 
deletion, known to cause a different phenotype with early onset juvenile polyposis, were 
excluded. A minority of patients had a missense mutation with uncertain pathogenicity, 
therefore a second statistical analysis without the data of these patients has been performed to 
determine whether the results were different.  
Descriptive results were reported as mean (range) for continuous variables and 
number (percentage) for categorical variables. The lifetime risk of benign and malignant 
gastrointestinal lesions was calculated by Kaplan-Meier methods. The observation time was 
from the date of birth until CRC, gastrointestinal polyps, death, or date of last contact, 
whichever came first. For the calculations, all patients were in the denominator, assuming 
that all patients had had gastrointestinal examinations. Statistical analyses were performed 




A total of 156 patients with documented deleterious PTEN mutations from 101 families 
were included. Sixty-seven (43%) were male. The patients were born between 1928 and 2008. 
The mean age at the date of last contact was 33 years (range 1-73 years). Forty-three patients 
(28%) were younger than 18 years at the date of last contact. Four patients had died at a mean 
age of 48 years (range 42-68 years), all of them had cancer.  
In 49 patients (31%), benign gastrointestinal lesions were reported. There was no familial 
clustering of polyps. The mean age at diagnosis of gastrointestinal lesions was 38 years (range 
18-62 years). All patients were above age 18 at the first diagnosis of gastrointestinal polyps. 
The polyp types included hamartomas (n=42), ganglioneuromas (n=8), adenomas (n=6), 
juvenile polyps (n=4), hyperplastic polyps (n=3), leiomyomas (n=2), lipomas (n=2), and a 
neurofibroma (n=1). Twenty-two patients (45%) had both upper as well as lower 
gastrointestinal lesions, 14 (29%) had only colorectal polyps, and for 13 (27%) patients, the 
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location of the polyps in the gastrointestinal tract were unknown. Different mutation sites 
were distributed evenly among patients with and without polyps. In figure 1, the cumulative 
lifetime risk of developing benign gastrointestinal lesions for patients with a PTEN gene 
mutation is shown. The risk was similar for both sexes (log rank test, p=0.181, figure not 
shown).  
Four patients (2.6%) developed colorectal cancer (CRC), all above age 50. 




Table 1 Characteristics of the four patients with colorectal cancer (CRC) 
 Gender Age CRC Previous GI findings Other cancer 
1 Male 57 >100 hamartomas and adenomas whole 
GI tract 
Carcinoid small intestine age 57 
Melanoma, age unknown 
Basal cell carcinoma age 62 
Renal cancer, age unknown  
2 Female 59 Leiomyomas and lipomas upper GI tract Carcinoid lung (at obduction) age 59 
DCIS* and LCIS** breast age 50 
3 Female 53 - Breast cancer age 50 
Thyroid cancer age 53 
4 Male 62 Leiomyoma and neurofibroma colon Clear cell renal carcinoma age 62 




The patients with CRC had all a different PTEN mutation site. All patients had at least one 
other malignant tumor at the time of diagnosis of CRC, including intestinal carcinoid, lung 
carcinoid, breast cancer, renal cancer, melanoma, and basal cell carcinoma. The lifetime risk 
of developing CRC for patients with a PTEN gene mutation was 18% by the age of 60 years 
(Figure 2).  
Thirteen patients had a missense mutation with uncertain pathogenicity. Statistical 
analysis without the data of these patients showed similar outcomes. 
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Figure 2 Cumulative lifetime risk of colorectal cancer (CRC) in patients with germline 












Age 0 10 20 30 40 50 60 70 
Number left in analysis 156 126 110 88 57 18 8 2 
Risk  0% 0% 0.9% 13.9% 25.3% 51.4% 69.4% 77.7% 
Age 50 60 70 
Number left in analysis 25 8 2 












DISCUSSION AND CONCLUSIONS 
The present study demonstrates that benign gastrointestinal lesions are common in PTEN 
mutation carriers and can occur at various ages. The most frequent findings were colorectal 
hamartomas. In this study, for patients with a PTEN gene mutation a three- to fourfold 
increased risk of developing colorectal cancer by the age of 60 years was observed, compared 
with the general population. Except for one small intestinal carcinoid, upper gastrointestinal 
malignancies were not observed. 
Two case reports describe Cowden patients with colorectal cancer at age 28, 39 and 56, 
respectively.[4,6] Furthermore, two recent studies have evaluated the occurrence of colorectal 
neoplasms in PHTS. A study from the USA reported nine CRC cases in 127 PTEN mutation 
carriers (7%), leading to an adjusted standardized incidence ratio (SIR) of 224.[5] In this 
study, all CRC diagnoses were between ages 35 and 49 years, but an age distribution was not 
provided in the article. Selection of patients was based on symptomatic Cowden Syndrome, or 
having gastrointestinal features. Another recent study evaluated CRC cases in Cowden 
syndrome patients in whom diagnosis was based on clinical criteria and not confirmed by 
DNA testing. Most of these cases were reported in the literature, and the authors added a 
small new patient series.[2] Five out of 211 patients (2.4%) developed CRC, with the earliest 
CRC diagnosis at age 43. A lifetime risk (by the age of 70 years) of CRC of 16% was 
calculated. These two cohort studies, and our study evidently show a three- to four times 
increased risk of CRC in PHTS patients, compared with the healthy population, as for people 
living in industrialized countries the cumulative lifetime risk of developing CRC is about 
5%.[7] 
Remarkably, in our series, we observed various types of polyps, but no cancers in the 
upper gastrointestinal tract, except one carcinoid of the small intestine. Reviewing the 
literature revealed three cases of gastric carcinoma, in PHTS patients at 67, 66 and 73 years 
old, respectively.[5,8,9]  
The mechanism of colorectal cancer development in PTEN mutation carriers remains 
unclear. Although hamartomas are considered as benign polyps, in the past, a hamartoma-
carcinoma sequence was suggested, caused by an abnormal microenvironment due to 
mutations, and leading to increased risks of neoplastic transformation.[10] A case study 
described a patient with a germline PTEN mutation who developed two independent CRCs at 
age 56. She had hamartomatous and hyperplastic polyposis throughout the gastrointestinal 
tract and the adenocarcinomas were shown to develop from the hyperplastic polypous 
lesions.[4] Of the three gastric cancers reported in the literature, two arose from a large 
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hyperplastic/hamartomatous polyp, but the other from an adenoma.[5,8,9] We were unable to 
determine whether the CRCs in our study arose from hamartomas or other types of colorectal 
polyps. A possible explanation for CRC development in PTEN mutation carriers was recently 
published. Huang et al. suggested that PTEN mutations seem not to be the single driving force 
for CRC development and that hMSH3 (mismatch repair) defects in nondysplastic epithelium 
may explain the increased risk of neoplastic progression of colonic hamartomas in PHTS 
patients.[11] 
Our study comprises unique data of a large cohort of PTEN mutation carriers, and is 
distinguished from the earlier cohort studies in that it is based on mutation carriers only. Due 
to the retrospective design of the study, there may be a selection bias for symptomatic patients 
and patients with cancer. However, the selection bias might be limited, as many submitted 
patients did not even meet the Cowden syndrome diagnostic criteria.[12] On the contrary, the 
calculated risks of polyps are most likely underestimations, as not all patients had full 
endoscopic examinations and thus some may still have undetected polyps.  
The most recent NCCN Guidelines for Cowden syndrome and other syndromes due to 
PTEN mutations do not provide specific recommendations for gastrointestinal surveillance in 
PHTS (0,13). Several investigators have suggested colorectal screening of PHTS patients. 
Some recommended biennial screening starting at age 15,[14] others proposed performing 
one baseline colonoscopy in asymptomatic patients at age 50,[15] or surveillance from the age 
of 25-30 years in a study setting.[6] The authors of the most recent studies recommend 
colonic surveillance starting at age 35, with follow-up examinations depending of the polyp 
burden,[5] and colonic surveillance starting at age 40 with 5-year intervals,[2] respectively. 
Based on our study and our review of the recent literature, for PHTS patients and patients 
with demonstrated PTEN mutations, we would propose performing surveillance 
colonoscopies every five years - or more frequently if polyps are discovered at baseline -, 
starting at age 40, or five years before the first CRC diagnosis in the family.  
In conclusion, patients with PTEN germline mutations have an increased risk of 
developing CRC, which warrants colorectal surveillance. The risk of upper gastrointestinal 
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The aim of this thesis was to describe clinical aspects of the hereditary polyposis syndromes 
familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), and PTEN 
hamartoma tumor syndrome (PHTS) to optimize the diagnosis, surveillance, and management 
of patients with these syndromes. In the Introduction (Chapter 1), we formulated several 
questions, which will be addressed below. 
 
Part I Familial adenomatous polyposis (FAP) 
 
Can genetic information be applied for management decisions in FAP? 
 
In Chapter 2, genotype-phenotype correlations for FAP were reviewed. Since the detection of 
the adenomatous polyposis coli (APC) gene in 1991 (1), many reports described an 
association between location of the APC mutation and the number of colorectal polyps. Based 
on reported genotype-phenotype correlations we proposed to define three genotypic regions 
and associated phenotypes: First, mutations before codon 157, after codon 1595, and the 
alternatively spliced region of codon 9 (codons 312-412) generally cause an attenuated 
phenotype with less than 100 colorectal polyps. Second, if the mutation is located between 
codons 1250-1464, profuse polyposis with thousands of colorectal polyps is expected. Third, 
mutations from codons 158-311, 413-1249, and 1465-1594 are correlated with an 
intermediate phenotype, characterized by development of hundreds to thousands of 
colorectal polyps. For extracolonic lesions, genotype-phenotype associations were less 
obvious. 
Using information on genotype-phenotype associations for clinical decisions was proposed in 
Chapters 3 and 4. The risk of rectal excision and rectal cancer after colectomy with ileorectal 
anastomosis (IRA) was assessed for patients with the attenuated, intermediate, and profuse 
genotype, respectively. As expected, in the groups with a genotype predicting a more severe 
polyposis phenotype the risk of rectal excision and rectal cancer was increased (61-74%  
versus 10% cumulative risk of rectal excision 20 years after primary IRA for profuse versus 
attenuated genotype groups, p=<0.05). Genetic information should never be the unique guide 
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for treatment decisions, as there may be intrafamilial phenotypic variation in FAP families. 
However, the combination of endoscopic and genetic data predicted the disease course, and 
can therefore be used to support clinical decisions. In a recent study, genotype-phenotype 
correlations were confirmed (2). Moreover, follow-up data for the different genotype groups 
were assessed, showing a reduced survival in the severe genotype group, compared to the 
milder genotype groups (2). 
 
Can risk factors be identified for postoperative fertility problems? 
 
Most FAP patients are in the fertile ages at the time of prophylactic colectomy. Information on 
the impact of IRA or IPAA on fertility in female FAP patients is scarce (3). We evaluated self-
reported postoperative fertility problems in a cohort of 138 female FAP patients (Chapter 5). 
Seventeen percent reported fertility problems due to surgery, which seems to be higher than 
the estimated rate of 10% subfertility complaints in the Dutch population (4). Our results 
showed no significant surgery- or disease related risk factors (type of surgery, indication, 
number of surgical procedures, complications, desmoid tumor, cancer, other comorbidity) for 
developing postoperative fertility problems. Women who reported fertility problems were 
significantly younger at the time of primary surgery than women not reporting fertility problems 
(22 versus 28 years, p=0.01). This finding suggests that extended abdominal surgery at a 
young age may lead to reduced fertility. The mechanism is most likely anatomical changes 
and scarring due to surgery, although there may be other factors as impaired sexual function, 
psychological distress, and fear of pouch problems after pregnancy and delivery (5). One 
previous study showed increased time to pregnancy in female FAP patients who had 
undergone total proctocolectomy with ileal pouch-anal anastomosis (IPAA) (3). Our results 
showed no difference between type of surgery and postoperative problems. The differences 
between this observation and our findings can be explained by different study designs. In a 
meta-analysis the risk of fertility problems after IPAA was confirmed and options for prevention 
and management of post-IPAA infertility were suggested, including delay of IPAA, rectum-
preserving surgery, embryo cryopreservation, and use of anti-adhesion products (5). 
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However, the studies included in this meta-analysis involved mainly ulcerative colitis patients. 
Therefore, further studies should focus on FAP patients. Furthermore, as publication bias 
cannot be excluded, future studies should preferably be prospective. 
 
What is the outcome of patients with advanced duodenal adenomatosis or duodenal cancer? 
 
Duodenal adenomatosis is very common in FAP patients (6). A subset of the patients develop 
duodenal cancer. To assess the clinical course of FAP patients with severe duodenal disease, 
all known cases with advanced duodenal adenomatosis (36/1066, 3.4%) and duodenal 
cancer (18/1066, 1.7%) were selected from the Dutch Polyposis Registry database (Chapter 
6). Patients with duodenal cancer had a poor prognosis with a median survival of eleven 
months. Prophylactic surgery in patients with advanced adenomatosis may prevent 
development of cancer, however, postoperative morbidity was considerable and even 
postoperative mortality was reported in three patients in our study. Furthermore, even after 
duodenectomy, fifty percent of the patients developed new adenomas in the neoduodenum. 
Nonetheless, the extremely poor prognosis of duodenal cancer justifies an aggressive surgical 
approach in patients with advanced duodenal adenomatosis. Patients should be under strict 
surveillance to control duodenal adenomatosis and to plan the optimal time for surgical 
intervention, if needed (7). 
 
What are the implications of recent findings on the Wnt pathway and type II diabetes? 
 
In the past years new techniques came available which enable rapid analysis of large amounts 
of genetic data. In genome wide analysis studies (GWAS) variants in the DNA sequence 
(single nucleotide polymorphisms, SNPs) are compared between cohorts of affected and non-
affected persons. SNPs occurring more frequently in the affected patients are suspected to be 
associated with the disease. The recent detection of an association between type II diabetes 
and TCF7L2 (or TCF4) polymorphisms (8) led us to the question whether this type of diabetes 
is more common in FAP patients, as TCF7L2 is a transcription factor involved in the Wnt-
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pathway, which is upregulated in FAP patients due to a germline APC mutation. In our study 
an increased prevalence of type II diabetes was found in FAP patients, compared with the 
general population (Chapter 7). Our clinical study indeed confirmed the laboratory findings 
and supported the hypothesis of Wnt-pathway involvement in type II diabetes (9). 
 
Part II Desmoid tumors 
 
What are the characteristics of FAP patients with desmoid tumors? Can differences between 
FAP-related and sporadic desmoids be used to predict a FAP syndrome? What are risk factors 
for desmoid tumor development? What is the outcome of different treatment strategies for 
desmoid tumors? 
 
In the Chapters 8, 9, 10, and 11, epidemiology-, etiology-, diagnosis-, and treatment issues on 
desmoid tumors are discussed. Desmoid tumors are a significant problem in FAP. FAP 
patients have a 14% lifetime risk of developing a desmoid tumor, and we found a substantial 
risk of 14% of dying from (complications of) desmoid disease in FAP patients with such a 
tumor (Chapter 8). Furthermore, secondary proctectomy was problematic or even impossible 
in seven patients.  
Comparison of clinical characteristics of FAP-related and sporadic desmoid tumors showed 
that a substantial number (at least 7.5%) of all desmoid tumors were associated with FAP, 
particularly in case of intra-abdominal or abdominal wall tumor locations (Chapter 9).  
Predicting the risk of developing a desmoid tumor may affect management decisions for FAP 
patients. Our study (Chapter 10) on 2260 European FAP patients, of which 220 had a desmoid 
tumor, showed that an APC mutation located 3’ of codon 1444 and previous abdominal 
surgery were signifcant risk factors for desmoid development (regardless tumor location). If 
only the intra-abdominal desmoid tumors were taken into account, only previous abdominal 
surgery was a significant risk factor. Furthermore, a family history of desmoid tumors was a 
significant risk factor for desmoid development, as also observed by others (10). Further 
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assessed factors, including age of desmoid diagnosis, sex, and colorectal cancer, did not 
show to be independent risk factors for desmoid development.  
In Chapter 11, we evaluated treatment modalities for FAP-related desmoid tumors including 
medical treatment (NSAIDs, anti-estrogens, other medication), surgery, and cytotoxic 
chemotherapy. For intra-abdominal desmoids, the progression-free survival was similar after 
surgery and a non-surgical approach (medicines, wait-and-see). In both groups, 
approximately two-thirds of tumors were stable or in regression, and about one fifth of patients 
died due to the desmoid tumor. For extra-abdominal and abdominal wall desmoids, surgery 
was the most common type of therapy with overall good outcome: three-quarter became 
stable or regressive, and no patients died in these groups. Evaluation of medical therapy 
showed similar progression-free survival in patients who received NSAIDs and hormonal 
therapy. Due to small numbers, effects of chemotherapy were difficult to interpret. 
Doxorubicin-based therapies seemed to be most effective. 
The outcome of our studies on desmoid tumors emphasize the significance of particularly 
intra-abdominal desmoid tumors. Based on our studies, we recommend the following 
approach. First, in each patient presenting with a desmoid tumor, the possibility of an 
underlying FAP syndrome should be kept in mind (11,12). To exclude FAP, we recommended 
to perform colonoscopy in all patients with a desmoid tumor under age 60 years, and all 
patients with intra-abdominal or abdominal wall desmoids regardless of age. Second, in 
patients who already have a diagnosis of FAP, risk factors for developing desmoids should be 
taken into account. As previous abdominal surgery is an evident risk factor, in a subset of 
patients colorectal surgery may be postponed, if possible. Moreover, the fact that family 
history is a risk factor implicates that genetic modifiers may be involved in desmoid 
development, which would be an interesting focus for future research (10). Third, for 
management of intra-abdominal desmoid tumors we recommend watchful waiting or 
pharmacological therapy. Recent literature also shows a tendency to watchful waiting in 
patients with stable desmoid tumors (13). Cytotoxic chemotherapy and surgery should be 
reserved for progressively growing tumors, or tumors causing obstruction. For extra-
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abdominal and abdominal wall desmoids, surgery seems to be safe, unless large 
postoperative defects are expected.  
 
Part III Other polyposis syndromes 
 
What is the natural course of MUTYH-associated polyposis? 
 
About a decade ago, a new polyposis gene, MUTYH, was discovered (14). Since then, many 
studies described characteristics of patients with MUTYH-associated polyposis (MAP) 
(15,16). Generally, MAP patients develop between ten and a few hundred colorectal 
adenomas from the age of 46-48 years, and many of them present with CRC (15,16) 
However, information on the natural history of this type of polyposis was limited. We assessed 
this topic in a multicenter study, in which we included 254 MAP patients from three countries 
(Chapter 12). Patients with a biallelic MUTYH mutation had a cumulative risk of developing 
CRC of 63% at age 60. Remarkably, among patients presenting with CRC, about half of the 
patients had less than 50 adenomas, and half of the patients had more than 50 adenomas. 
The number of colorectal polyps seems not to play an important role in CRC development. 
Another remarkable finding was that patients who presented with CRC had a considerable risk 
of developing a secondary CRC (11% after 5 years). Also, the patients presenting with 
colorectal adenomas had a substantial cumulative risk of CRC of 10% after 5 years of follow-
up. These findings suggest accelerated adenoma to carcinoma development in MAP patients. 
Possibly, DNA repair genes involved in Lynch syndrome play a role in CRC development in 
MAP, which could explain accelerated tumor development. In other studies, a link between 
base excision repair and low-frequency MSI-pathways (17) and MLH1 gene as a target of 
MUTYH transversions (18) were suggested. Although MAP in most cases displays an 
attenuated polyposis phenotype, our study showed rapid CRC progression. Therefore, 




What is the risk of gastrointestinal lesions in patients with a PTEN mutation? 
 
PTEN hamartoma tumor syndrome (PHTS) is characterized by a high risk of developing 
benign hamartomatous lesions and a high risk of developing malignant tumors, particularly of 
the breast, thyroid, and endometrium. Screening programs are designed to detect these 
tumors at an early stage. In Chapter 13, we evaluated the frequency of benign and malignant 
colorectal tumors in a cohort of 156 patients with a germline PTEN mutation, retrieved from 
nine countries. We calculated a cumulative lifetime risk to develop benign colorectal lesions of 
69% at age 60 years. The most frequent findings were hamartomatous polyps. Nearly half of 
the patients with colorectal tumors had also upper gastrointestinal lesions. Four patients were 
reported to have colorectal cancer (ages 53, 57, 59, 62 years). The cumulative risk of CRC at 
age 60 was 18%, which is about three- to fourfold increased compared with the general 
population. We were not informed whether the cancers developed from hamartomas or other 
colonic lesions. However, based on our results and similar findings in recent studies (19,20), 
we propose colonosopic surveillance every five years starting at the age of 40 years, or five 
years before the first CRC diagnosis in the family.    
 
Concluding remarks 
This thesis shows the complexity of establishing guidelines for management of hereditary 
tumor syndromes. As most of these syndromes are rare, most recommendations are based on 
small patient numbers and retrospective analyses, whereas performing prospective 
randomized studies in large study cohorts would be preferred. Large international research 
collaborations may overcome this problem. Furthermore, clustering of patients with rare and 
complex diseases in specialized hospitals will optimize treatment. Clinical guidelines for 
treatment of these patients should not be considered as rigid instructions, but should be used 
as a support in decision making. Eventually, multidisciplinary decision making with the clinical 
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Nederlandse samenvatting 
In dit proefschrift worden klinische aspecten van de erfelijke polyposissyndromen familiaire 
adenomateuze polyposis (FAP), MUTYH-geassocieerde polyposis (MAP) en PTEN 
hamartoma tumor syndroom (PHTS) beschreven. Het doel hiervan is optimalisatie van 
diagnostiek, periodieke controle en behandeling van patiënten met deze syndromen. In de 
Introductie (Hoofdstuk 1) werden diverse onderzoeksvragen geformuleerd, die hieronder 
behandeld worden. 
 
Deel I Familiaire adenomateuze polyposis (FAP) 
 
Kan genetische informatie worden toegepast bij beslissingen over de behandeling van FAP? 
 
Hoofdstuk 2 is een overzichtsartikel waarin genotype-fenotypecorrelaties worden beschreven. 
Sinds de ontdekking van het APC-gen in 1991 toonden veel studies een associatie aan tussen 
de plaats van de mutatie op het APC-gen en het aantal colorectale poliepen. Op basis van 
deze studies stellen wij voor om het APC-gen te verdelen in drie regio’s (genotypes) met 
bijbehorend aantal poliepen (fenotypes): het eerste genotype betreft mutaties voor codon 157, 
na codon 1595 en in de alternatieve splice site regio van codon 9 (codon 312-412); deze 
veroorzaken over het algemeen een mild fenotype met minder dan 100 colorectale poliepen. 
Het tweede genotype betreft mutaties tussen codon 1250 en 1464, waarbij een zeer ernstig 
fenotype wordt verwacht met duizenden colorectale poliepen. Het derde genotype, met 
mutaties in de codons 158-311, 413-1249 en 1465-1594 is geassocieerd met een intermediair 
fenotype, gekenmerkt door honderd tot duizend colorectale poliepen. Voor tumoren buiten de 
darm, die frequent voorkomen bij FAP, werden geen duidelijke genotype-fenotypecorrelaties 
gevonden. 
In de hoofdstukken 3 en 4 stellen wij voor om informatie over genotype-fenotypecorrelaties te 
gebruiken bij klinische besluitvorming. Een cohort FAP-patiënten werd op basis van de plaats 
van de mutatie ingedeeld in de bovenbeschreven groepen. Vervolgens werd het risico op 
rectumexcisie en rectumcarcinoom na colectomie met ileorectale anastomose (IRA) 
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berekend. Zoals verwacht hadden de groepen met een genotype dat een ernstiger fenotype 
voorspelt een hoger risico op rectumexcisie en rectumcarcinoom (61-74% versus 10% 
cumulatief risico op rectumexcisie 20 jaar na primaire IRA voor ernstig versus mild genotype, 
p<0.05). Genetische informatie mag nooit de enige richtlijn zijn voor besluitvorming rond een 
behandeling, omdat  het fenotype binnen een familie met FAP sterk kan variëren. Echter, op 
basis van een combinatie van endoscopische en genetische gegevens kan het ziektebeloop 
voorspeld worden. Een recente studie bevestigde genotype-fenotypecorrelaties en toonde in 
een patiëntengroep met een ernstig genotype een kortere overlevingsduur dan in een groep 
met mildere genotypes. 
 
Kunnen risicofactoren worden geïdentificeerd voor het optreden van postoperatieve 
fertiliteitsproblemen? 
 
De meeste FAP-patiënten ondergaan een profylactische colectomie tijdens de jaren waarin zij 
vruchtbaar zijn. Informatie over de gevolgen van een ileorectale anastomose (IRA) of ileo-
pouch-anale anastomose (IPAA) op de fertiliteit van vrouwen is beperkt. Wij evalueerden in 
een cohort van 138 vrouwen met FAP door hen gerapporteerde postoperatieve 
fertiliteitsproblemen. Zeventien procent meldde fertiliteitsproblemen als gevolg van de 
colectomie. Dit percentage is iets hoger dan de geschatte subfertiliteit in de algemene 
Nederlandse populatie (ongeveer 10%). In onze studie werd geen significant verband 
aangetoond tussen postoperatieve fertiliteitsproblemen en operatie- of ziektegebonden 
factoren zoals type operatie, indicatie, aantal operaties, complicaties, desmoidtumor, kanker 
of overige comorbiditeit. Vrouwen die fertiliteitsproblemen rapporteerden waren significant 
jonger ten tijde van de eerste operatie dan vrouwen zonder problemen (22 versus 28 jaar, p= 
0.01), wat suggereert dat een uitgebreide buikoperatie op jonge leeftijd kan leiden tot 
verminderde fertiliteit. Dit wordt meest waarschijnlijk veroorzaakt door anatomische 
veranderingen en vorming van littekenweefsel als gevolg van de operatie, hoewel ook andere, 
bijvoorbeeld psychologische factoren een rol kunnen spelen. Een eerdere studie beschreef 
dat het bij vrouwen met FAP die een IPAA hadden ondergaan langer duurde tot ze zwanger 
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waren dan voor vrouwen die een IRA hadden ondergaan. In onze studie wordt geen verschil 
gezien tussen type operatie en postoperatieve fertiliteitsproblemen. Dit kan verklaard worden 
doordat wij een andere onderzoeksmethode gebruikten. In een recente meta-analyse werd 
het risico op fertiliteitsproblemen na IPAA bevestigd en werden opties voor preventie en 
behandeling voorgesteld, zoals uitstellen van de operatie, rectumsparende operatie, 
embyocryopreservatie en gebruik van anti-adhesieve producten. Het merendeel van de 
studies die in deze meta-analyse werden geïncludeerd onderzocht echter patiënten met colitis 
ulcerosa. Toekomstige studies zouden bij voorkeur gericht moeten zijn op FAP-patiënten. 
Bovendien kan bij een meta-analyse publicatiebias niet worden uitgesloten; toekomstige 
studies zouden daarom prospectief opgezet moeten worden. 
 
Wat is de uitkomst van patiënten met gevorderde adenoomvorming in het duodenum of 
duodenumcarcinoom? 
 
Veel patiënten met FAP hebben ook adenomen in het duodenum. Een deel van hen ontwikkelt 
duodenumcarcinoom. Om het klinische beloop van FAP-patiënten met een ernstig aangedaan 
duodenum te onderzoeken werden uit de polyposisregistratie van de Stichting Opsporing 
Erfelijke Tumoren alle patiënten met gevorderde adenoomvorming (36/1066, 3,4%) of kanker 
(18/1066, 1,7%) van het duodenum geselecteerd (Hoofdstuk 6). Patiënten met 
duodenumcarcinoom hadden een slechte prognose; de mediane overleving was elf maanden. 
Ontwikkeling van kanker kan worden voorkomen door profylactische duodenectomie, hoewel 
er bij deze operatie een aanzienlijke kans is op postoperatieve morbiditeit en zelfs mortaliteit. 
Bovendien ontwikkelde 50% van de patiënten na de operatie nieuwe adenomen in het 
neoduodenum. Desondanks rechtvaardigt de extreem slechte prognose van 
duodenumkanker agressieve chirurgische interventie in patiënten met gevorderde 
duodenumadenomen. Om adenoomvorming van het duodenum te controleren en het 




Wat zijn de implicaties van recente bevindingen van betrokkenheid van de Wnt-pathway bij 
type II diabetes? 
 
In de afgelopen jaren zijn diverse technieken ontwikkeld die snelle analyse van grote 
hoeveelheden genetische informatie mogelijk maken. Genoomwijde analyses (GWAS) 
worden gebruikt om varianten in het DNA (single nucleotide polymorphisms, SNPs) te 
vergelijken tussen aangedane en niet-aangedane personen. SNPs die vaker voorkomen in 
aangedane personen zijn mogelijk geassocieerd met de betreffende ziekte. De recente 
ontdekking van een associatie tussen type II diabetes en TCF7L2 (of TCF4) polymorfismen 
riep bij ons de vraag op of type II diabetes vaker voorkomt bij FAP-patiënten, omdat TCF7L2 
als transcriptiefactor functioneert in de Wnt-pathway die geactiveerd is in patiënten met een 
APC mutatie in de kiembaan. In onze studie vonden we een hogere prevalentie van type II 
diabetes in patiënten met FAP ten opzichte van de algemene populatie (Hoofdstuk 7). Deze 
klinische studie bevestigt de eerder beschreven laboratoriumbevindingen en ondersteunt de 
hypothese dat de Wnt-pathway betrokken is bij type II diabetes. 
 
Deel II Desmoidtumoren 
 
Wat zijn de kenmerken van FAP-patiënten met desmoidtumoren? Kunnen verschillen tussen 
FAP-gerelateerde- en sporadische desmoiden gebruikt worden om FAP te voorspellen? Wat 
zijn risicofactoren voor de ontwikkeling van desmoidtumoren? Wat is de uitkomst van 
verschillende behandelstrategieën voor desmoidtumoren? 
 
In de hoofdstukken 8, 9, 10 en 11 worden epidemiologie, etiologie, diagnose en behandeling 
van desmoidtumoren besproken. Desmoidtumoren zijn een aanzienlijk probleem bij FAP. 
FAP-patiënten hebben gedurende hun leven 14% kans een desmoidtumor te ontwikkelen en 
onze studie toonde dat het risico om te overlijden aan (complicaties van) de desmoidtumor 
substantieel is (14%) (Hoofdstuk 8). Bovendien was een secundaire proctectomie in een 
aantal gevallen problematisch of zelfs onmogelijk door een desmoidtumor.  
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Klinische kenmerken van FAP-gerelateerde- en sporadische desmoidtumoren werden 
vergeleken in Hoofdstuk 9. Deze studie toonde dat minimaal 7.5% van alle desmoidtumoren is 
geassocieerd met FAP, vooral bij lokalisatie van de tumor in het abdomen of in de buikwand.  
Als het risico op een desmoidtumor voorspeld kan worden zou het beleid hierop afgestemd 
kunnen worden. Onze studie (Hoofdstuk 10) in 2260 Europese FAP-patiënten, waarvan 220 
met een desmoidtumor, toonde dat een APC-mutatie 3’ van codon 1444 en abdominale 
chirurgie in het verleden significante risicofactoren zijn voor het ontwikkelen van een 
desmoidtumor, ongeacht de lokalisatie. Bij subanalyse van het risico op intra-abdominale 
desmoiden bleek alleen abdominale chirurgie in het verleden een significante risicofactor te 
zijn. Ook was het voorkomen van desmoidtumoren bij familieleden een significante 
risicofactor voor het ontwikkelen van desmoiden. Dit is eerder ook beschreven. Andere 
onderzochte factoren zoals leeftijd van diagnose van de desmoidtumor, geslacht en 
colorectaal carcinoom waren geen onafhankelijke risicofactoren voor de ontwikkeling van 
desmoidtumoren. 
In Hoofdstuk 11 evalueerden we de diverse behandelmodaliteiten voor desmoidtumoren zoals 
medicamenten (non-steroidal anti-inflammatory drugs (NSAIDs), anti-oestrogeentherapie, 
andere medicatie), chirurgie en chemotherapie. Bij intra-abdominale desmoidtumoren was de 
progressievrije overleving vergelijkbaar na een chirurgische of een niet-chirurgische 
benadering (medicijnen of afwachtend beleid). In beide groepen bereikte ongeveer tweederde 
een stabiele situatie of regressie van de desmoidtumor, en ongeveer eenvijfde van de 
patiënten overleed ten gevolge van de desmoidtumor. Extra-abdominale- en 
buikwanddesmoiden werden in de meeste gevallen chirurgisch verwijderd met globaal goede 
uitkomsten; driekwart bleef stabiel of ging in regressie en in deze groepen overleden geen 
patiënten aan de desmoidtumor. Evaluatie van medicamenteuze therapieën toonde een 
vergelijkbare progressievrije overlevingsduur in patiënten die NSAIDs of hormonale medicatie 
gebruikten. Effecten van chemotherapie waren moeilijk te interpreteren vanwege het kleine 
aantal personen dat op deze manier behandeld werd. Chemotherapie met doxorubicine leek 
het meest effectief te zijn. 
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De uitkomst van deze vier studies naar desmoidtumoren benadrukken de ernst van met name 
intra-abdominale desmoidtumoren. Op basis van onze resultaten stellen wij de volgende 
benadering voor. Ten eerste moet in het geval dat een patiënt zich presenteert met een 
desmoidtumor de mogelijkheid van FAP in gedachten worden gehouden. Wij adviseren 
colonoscopie in alle patiënten die zich op de leeftijd van 60 jaar of jonger met een 
desmoidtumor presenteren en alle patiënten met een intra-abdominale- of 
buikwanddesmoidtumor ongeacht de leeftijd. Ten tweede, bij patiënten met FAP moet 
rekening worden gehouden met de risicofactoren voor desmoidontwikkeling. Omdat een 
voorgeschiedenis van abdominale chirurgie een duidelijke risicofactor is moet in overweging 
worden genomen of colorectale chirurgie kan worden uitgesteld. Het feit dat een positieve 
familieanamnese een risicofactor is veronderstelt dat genetische modifiers een rol spelen bij 
het ontstaan van desmoidtumoren. Dit is een interessant onderwerp voor toekomstig 
onderzoek. Ten derde adviseren wij als behandeling voor intra-abdominale desmoidtumoren 
een afwachtend beleid of medicamenteuze therapie. Recente onderzoeken tonen een trend 
richting een afwachtend beleid in patiënten met een stabiele desmoidtumor. Chemotherapie 
en chirurgie moeten gereserveerd worden voor progressief groeiende tumoren, of desmoiden 
die obstructie veroorzaken. In geval van extra-abdominale- of buikwanddesmoiden lijkt 
chirurgie een veilige optie te zijn, tenzij grote postoperatieve defecten verwacht worden.  
 
Deel III Andere polyposissyndromen 
 
Wat is het natuurlijk beloop van MUTYH-geassocieerde polyposis? 
 
Ongeveer tien jaar geleden werd een nieuw polyposisgen ontdekt: MUTYH. Sindsdien zijn 
vele studies verschenen die de kenmerken van patiënten met MUTYH-geassocieerde 
polyposis (MAP) beschrijven. Meestal ontwikkelen MAP-patiënten tussen de tien en enkele 
honderden colorectale adenomen vanaf ongeveer 46-jarige leeftijd, en velen presenteren zich 
met colorectaal carcinoom (crc). Er was echter weinig bekend over het natuurlijk beloop van 
MAP. Wij onderzochten dit onderwerp in een studie waarbij samengewerkt werd met diverse 
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andere instituten. Er werden 254 MAP-patiënten uit drie verschillende landen geïncludeerd. 
Patiënten met een biallelische MUTYH-mutatie hebben op 60-jarige leeftijd een cumulatief 
risico op crc van 63%. Een opmerkelijke bevinding was dat van de patiënten die zich 
presenteerden met crc ongeveer de helft minder dan 50 adenomen had, en de helft meer dan 
50 adenomen. Dit veronderstelt dat het aantal adenomen niet een belangrijke rol speelt bij het 
risico op het ontstaan van crc. Een andere opmerkelijke bevinding was dat patiënten die zich 
met crc presenteerden een aanzienlijk risico hadden op een tweede crc (11% na 5 jaar). Ook 
patiënten die bij eerste diagnose alleen adenomen hadden bleken een cumulatief risico op crc 
te hebben van 10% na 5 jaar follow-up. Deze bevindingen suggereren dat er een versnelde  
adenoom-tot-carcinoom-ontwikkeling is in patiënten met MAP. Mogelijk spelen DNA-
herstelgenen hierbij een rol, die ook zijn betrokken bij Lynch syndroom. In recente studies 
werd een link verondersteld tussen base excision repair en laag-frequente MSI-pathways. 
Ook werd gesuggereerd dat het MLH1-gen mogelijk een doel is van MUTYH-transversies. 
Hoewel de meeste MAP-patiënten een mild polyposis fenotye hebben toont onze studie dat er 
een snelle ontwikkeling van adenoom naar crc kan zijn. Daarom zijn intensieve periodieke 
controles van het colorectum geïndiceerd in deze patiënten. 
 
Wat is risico op gastrointestinale afwijkingen bij patiënten met een mutatie in het PTEN-gen? 
 
Het PTEN hamartoma tumor syndroom (PHTS) wordt gekenmerkt door een hoog risico op 
ontwikkeling van maligne tumoren, met name in borst, schildklier en endometrium. Om deze 
tumoren in een zo vroeg mogelijk stadium te ontdekken zijn screeningsprogramma’s 
ontwikkeld. In hoofdstuk 13 evalueren we de frequentie van goedaardige en kwaadaardige 
colorectale tumoren in een cohort van 156 patiënten met een PTEN-mutatie in de kiembaan. 
Patiëntgegevens uit negen landen werden verzameld. Het cumulatief risico op het ontwikkelen 
van goedaardige afwijkingen in de darm was 69% op de leeftijd van 60 jaar. Meest 
voorkomend waren hamartomateuze poliepen. Bijna de helft van de patiënten had ook 
afwijkingen in de bovenste tractus digestivus. Vier patiënten ontwikkelden crc op de leeftijd 
van 53, 57, 59 en 62 jaar, respectievelijk. Het cumulatief risico op crc was 18% op 60-jarige 
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leeftijd, wat ongeveer drie- tot vier keer verhoogd is ten opzichte van de algemene populatie. 
We hadden geen informatie of deze crc's ontstaan waren uit hamartomen of uit andere 
afwijkingen. Op basis van ons onderzoek en vergelijkbare bevindingen in eerdere studies 
stellen wij voor om bij patiënten met PHTS iedere vijf jaar een colonoscopie te verrichten, of 
vaker, afhankelijk van de bevindingen. Dit zou gestart kunnen worden vanaf 40-jarige leeftijd 
of vijf jaar vóór de eerste diagnose van crc in de familie.  
 
Afsluitende opmerkingen 
Dit proefschrift toont dat het maken van richtlijnen voor erfelijke polyposissyndromen een 
complexe zaak is. De meeste van deze syndromen zijn zeldzaam, waardoor veel 
aanbevelingen gebaseerd zijn op kleine patiëntgroepen en retrospectieve analyses, terwijl 
studies bij voorkeur worden uitgevoerd als prospectief gerandomiseerd onderzoek in grote 
patiëntcohorten. Dit probleem kan worden opgelost door internationale samenwerking. De 
behandeling van patiënten met zeldzame en complexe aandoeningen zal optimaal zijn als 
deze wordt geconcentreerd in gespecialiseerde centra. Klinische richtlijnen moeten niet 
gezien worden als starre voorschriften, maar moeten gebruikt worden als ondersteuning bij 
klinische besluitvorming. De meest optimale behandeling zal uiteindelijk gekozen kunnen 
worden door middel van multidisciplinaire besluitvorming, waarbij klinische experts, de patiënt 
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